Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Hypera Pharma
Deal Size : $825.0 million
Deal Type : Divestment
Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma
Details : The divested portfolio includes select over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, and other South American, Central American and Caribbean countries, which are part of Takeda’s Growth & Emerging Markets Business U...
Product Name : Neosaldina
Product Type : Dietary Supplement
Upfront Cash : Undisclosed
January 29, 2021
Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Hypera Pharma
Deal Size : $825.0 million
Deal Type : Divestment
Lead Product(s) : Metamizole
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Brainfarma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dipyrone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain, Postoperative.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 23, 2020
Lead Product(s) : Metamizole
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Brainfarma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Hypera Pharma
Deal Size : $825.0 million
Deal Type : Divestment
Details : The portfolio includes over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru, which are part of Takeda’s Business Unit.
Product Name : Neosaldina
Product Type : Dietary Supplement
Upfront Cash : Undisclosed
March 02, 2020
Lead Product(s) : Caffeine,Isometheptene Mucate,Metamizole
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Hypera Pharma
Deal Size : $825.0 million
Deal Type : Divestment
Lead Product(s) : Metamizole
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Metamizole is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Stroke.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 09, 2014
Lead Product(s) : Metamizole
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metamizole
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Metamizol for the Treatment of Neoplastic Chronic Pain
Details : Metamizole is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2014
Lead Product(s) : Metamizole
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metamizole
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache
Details : Metamizole is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2014
Lead Product(s) : Metamizole
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
